Atorvastatin for reduction of 28-day mortality in severe and critical COVID-19 patients: a randomized controlled trial

Atorvastatin for reduction of 28-day mortality in severe and critical COVID-19 patients: a randomized controlled trial

Abstract Background COVID-19 is an abnormal host response to the SARS-CoV-2 infection, which is associated with endothelial dysfunction and multi-organ failure. Atorvastatin has been proposed to reduce COVID-19 severity and mortality in chronic and de-novo users. Methods This randomized double-blind...

Full description

Bibliographic Details
Main Authors: Naglaa Hamdi Eltahan, Neamat Hamdy Elsawy, Kholoud M. Abdelaaty, Amal Salah Elhamaky, Ahmed H. Hassan, Moataz Maher Emara
Format: Article
Language:English
Published: BMC 2024-02-01
Series:Respiratory Research
Subjects:
COVID-19
SARS-CoV-2
Coronavirus
Statins, hmg coa
Atorvastatin
Mortality
Online Access:https://doi.org/10.1186/s12931-024-02732-2

Internet

https://doi.org/10.1186/s12931-024-02732-2

Similar Items